MedPath

Altrubio Inc.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

4

Active:0
Completed:2

Trial Phases

2 Phases

Phase 1:2
Phase 2:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials

Phase 1
2 (50.0%)
Phase 2
2 (50.0%)

Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics

Phase 2
Recruiting
Conditions
Ulcerative Colitis
Interventions
First Posted Date
2023-10-31
Last Posted Date
2025-06-03
Lead Sponsor
AltruBio Inc.
Target Recruit Count
50
Registration Number
NCT06109441
Locations
🇺🇸

San Diego Gastroenterology, San Diego, California, United States

🇺🇸

Rocky Mountain Gastroenterology, Littleton, Colorado, United States

🇺🇸

Gastro Health Research, Miami, Florida, United States

and more 20 locations

A First-In-Human SAD and MAD Study to Evaluate the Safety, Tolerability, PK and PD of SC Administered ALTB-268 in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy Volunteers
First Posted Date
2023-02-13
Last Posted Date
2024-02-06
Lead Sponsor
AltruBio Inc.
Target Recruit Count
56
Registration Number
NCT05723692
Locations
🇺🇸

ICON Early Development Services, Lenexa, Kansas, United States

Neihulizumab (ALTB-168) in Patients With Steroid-refractory Acute Graft-versus-host Disease or Treatment-refractory Acute Graft-versus-host Disease

Phase 1
Completed
Conditions
Treatment-refractory Acute Graft-versus-Host Disease
Steroid-refractory Acute Graft-versus-Host Disease
First Posted Date
2017-11-01
Last Posted Date
2023-01-19
Lead Sponsor
AltruBio Inc.
Target Recruit Count
37
Registration Number
NCT03327857
Locations
🇺🇸

City of Hope, Duarte, California, United States

🇺🇸

David Geffen School of Medicine at UCLA, Los Angeles, California, United States

🇺🇸

University of Miami - Sylvester Comprehensive Cancer Center, Miami, Florida, United States

and more 10 locations

Efficacy&Safety of ALTB-168 in Patients With Moderate to Severe Active,Anti-TNF Alpha and/or Anti-integrin Refractory UC

Phase 2
Terminated
Conditions
Ulcerative Colitis
First Posted Date
2017-09-29
Last Posted Date
2024-01-05
Lead Sponsor
AltruBio Inc.
Target Recruit Count
24
Registration Number
NCT03298022
Locations
🇺🇸

Lynn Institute of the Ozarks, Little Rock, Arkansas, United States

🇺🇸

Stomach Doctor - Surinder Saini, MD - Fountain Valley, Newport Beach, California, United States

🇵🇷

Wellness Clinical Research (WCR), Vega Baja, Puerto Rico

and more 7 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.